Select Publications

Book Chapters

Covelli AM; Joshua AM; Lipa JE; Butler MO; Snell L; Sun A; Wright FC, 2020, 'Merkel Cell Carcinoma', in Surgical Oncology Manual, Springer International Publishing, pp. 333 - 343, http://dx.doi.org/10.1007/978-3-030-48363-0_17

Lim DW; Yin L; Racz JM; Joshua AM; Abadir WWK; Butler MO; Lipa JE; Sun A; Wright FC, 2020, 'Non-melanoma Skin Cancer', in Surgical Oncology Manual, Springer International Publishing, pp. 383 - 393, http://dx.doi.org/10.1007/978-3-030-48363-0_19

Racz J; Joshua AM; Lipa JE; Sun A; Wright FC, 2016, 'Merkel Cell Carcinoma', in Surgical Oncology Manual, Springer International Publishing, pp. 189 - 196, http://dx.doi.org/10.1007/978-3-319-26276-5_14

Racz J; Joshua AM; Lipa JE; Sun A; Wright FC, 2016, 'Non-melanoma Skin Cancer', in Surgical Oncology Manual, Springer International Publishing, pp. 225 - 232, http://dx.doi.org/10.1007/978-3-319-26276-5_17

Journal articles

Zhang J; Joshua AM; Li Y; O'Meara CH; Morris MJ; Khachigian LM, 2024, 'Targeted therapy, immunotherapy, and small molecules and peptidomimetics as emerging immunoregulatory agents for melanoma', Cancer Letters, 586, http://dx.doi.org/10.1016/j.canlet.2024.216633

Hall A; Crumbaker M; Pham J; Liu JJ; Sim H-W; Joshua AM, 2024, 'A meta-analysis of overall survival and response in metastatic adrenocortical carcinoma: A review of 23 prospective trials of 880 patients.', Journal of Clinical Oncology, 42, pp. 4 - 4, http://dx.doi.org/10.1200/jco.2024.42.4_suppl.4

Conduit C; Davis ID; Goh JC; Kichenadasse G; Gurney H; Harris CA; Pook D; Krieger L; Parnis F; Underhill C; Adams D; Roncolato F; Joshua A; Ferguson T; Prithviraj P; Morris M; Harrison M; Begbie S; Hovey E; George M; Liow EC; Link EK; McJannett M; Gedye C, 2024, 'A phase II trial of nivolumab followed by ipilimumab and nivolumab in advanced non-clear-cell renal cell carcinoma', BJU International, 133, pp. 57 - 67, http://dx.doi.org/10.1111/bju.16190

Azad A; Voskoboynik M; Joshua AM; Weickhardt AJ; Sankey P; Pacey S; Heath EI; Krieger L; Horvath L; Pilié PG; Womersley L; Linardopoulos S; Moorthy G; Zhou TJ; Brown J; de Paula B; Lukacs E; Hudson A, 2024, 'PETRANHA: Phase 1/2 study of AZD5305 + novel hormonal agents in patients with metastatic prostate cancer–Interim safety and pharmacokinetic results.', Journal of Clinical Oncology, 42, pp. 123 - 123, http://dx.doi.org/10.1200/jco.2024.42.4_suppl.123

Yu EY; Joshua AM; Kramer G; Shore ND; Hu H; Poehlein CH; Schloss C; De Bono JS, 2024, 'Phase 1b/2 study of pembrolizumab (pembro) plus platinum/etoposide and platinum/etoposide for neuroendocrine metastatic prostate cancer (NEPC): KEYNOTE-365 cohort I.', Journal of Clinical Oncology, 42, pp. TPS249 - TPS249, http://dx.doi.org/10.1200/jco.2024.42.4_suppl.tps249

Yu EY; Joshua AM; Shore ND; Kramer G; Hu H; Poehlein CH; Schloss C; De Bono JS, 2024, 'Phase 1b/2 study of pembrolizumab plus belzutifan and belzutifan alone in patients with docetaxel-treated metastatic castration-resistant prostate cancer (mCRPC): KEYNOTE-365 cohort J.', Journal of Clinical Oncology, 42, pp. TPS250 - TPS250, http://dx.doi.org/10.1200/jco.2024.42.4_suppl.tps250

Tan Q; Joshua AM; Wang M; Bristow RG; Wouters BG; Allen CJ; Tannock IF, 2024, 'Correction to: Up-regulation of autophagy is a mechanism of resistance to chemotherapy and can be inhibited by pantoprazole to increase drug sensitivity (Cancer Chemotherapy and Pharmacology, (2017), 79, 5, (959-969), 10.1007/s00280-017-3298-5)', Cancer Chemotherapy and Pharmacology, http://dx.doi.org/10.1007/s00280-023-04636-2

Hofman MS; Emmett L; Sandhu S; Iravani A; Buteau JP; Joshua AM; Goh JC; Pattison DA; Tan TH; Kirkwood ID; Ng S; Francis RJ; Gedye C; Rutherford NK; Weickhardt A; Scott AM; Lee ST; Kwan EM; Azad AA; Ramdave S; Redfern AD; Macdonald W; Guminski A; Hsiao E; Chua W; Lin P; Zhang AY; Stockler MR; Williams SG; Martin AJ; Davis ID; Akhurst T; Alipour R; Bailey D; Banks P; Beaulieu A; Campbell L; Crumbaker M; Dhiantravan N; Hamid A; Haskali M; Hung T; Kong G; Lawrence N; Lewin J; McCarthy M; Moodie K; Murphy D; Nguyen A; Pook D; Ravi Kumar A; Roach P; Roselt P; Saghebi J; Schembri G; Spain L; Subramaniam S; Thang SP; Thomas P; Tran B; Wallace R; Yip S, 2024, 'Overall survival with [177Lu]Lu-PSMA-617 versus cabazitaxel in metastatic castration-resistant prostate cancer (TheraP): secondary outcomes of a randomised, open-label, phase 2 trial', The Lancet Oncology, 25, pp. 99 - 107, http://dx.doi.org/10.1016/S1470-2045(23)00529-6

Hassel JC; Piperno-Neumann S; Rutkowski P; Baurain JF; Schlaak M; Butler MO; Sullivan RJ; Dummer R; Kirkwood JM; Orloff M; Sacco JJ; Ochsenreither S; Joshua AM; Gastaud L; Curti B; Piulats JM; Salama AKS; Shoushtari AN; Demidov L; Milhem M; Chmielowski B; Kim KB; Carvajal RD; Hamid O; Collins L; Ranade K; Holland C; Pfeiffer C; Nathan P, 2023, 'Three-Year Overall Survival with Tebentafusp in Metastatic Uveal Melanoma', New England Journal of Medicine, 389, pp. 2256 - 2266, http://dx.doi.org/10.1056/NEJMoa2304753

Liu J; Minchom AR; Greystoke A; Evans TRJ; Sarker D; Joshua AM; Morton C; Gaus A; Yau W; Cosman R; Chwialkowska D; Paull JRA; Jean-Francois BM; Fairley JK; Main NJ; Edmondson SR; Cook N, 2023, 'Abstract B039: A phase 1/2 study of dendrimer-enhanced (DEP) SN38 (SN38-SPL9111/DEP irinotecan) in patients with advanced solid tumours', Molecular Cancer Therapeutics, 22, pp. B039 - B039, http://dx.doi.org/10.1158/1535-7163.targ-23-b039

Crumbaker M; Goldstein LD; Murray DH; Tao J; Pathmanandavel S; Boulter N; Ratnayake L; Joshua AM; Kummerfeld S; Emmett L, 2023, 'Circulating Tumour DNA Biomarkers Associated with Outcomes in Metastatic Prostate Cancer Treated with Lutetium-177-PSMA-617', European Urology Open Science, 57, pp. 30 - 36, http://dx.doi.org/10.1016/j.euros.2023.08.007

Fleshner NE; Sayyid RK; Hansen AR; Chin JLK; Fernandes R; Winquist E; van der Kwast T; Sweet J; Lajkosz K; Kenk M; Hersey K; Veloso R; Berlin D; Herrera-Caceres JO; Sridhar S; Moussa M; Finelli A; Hamilton RJ; Kulkarni GS; Zlotta AR; Joshua AM, 2023, 'Neoadjuvant Cabazitaxel plus Abiraterone/Leuprolide Acetate in Patients with High-Risk Prostate Cancer: ACDC-RP Phase II Trial', Clinical Cancer Research, 29, pp. 3867 - 3874, http://dx.doi.org/10.1158/1078-0432.CCR-23-0731

Ardolino LC; Dear R; Armstrong AJ; Gillessen S; Joshua AM, 2023, 'Re: Timothée Olivier, Kerrington Powell, Vinay Prasad. Lutetium-177-PSMA-617 in Metastatic Castration-resistant Prostate Cancer: Limitations of the VISION Trial. Eur Urol. 2023;84:4–6', European Urology, 84, pp. e94 - e95, http://dx.doi.org/10.1016/j.eururo.2023.04.043

Pook D; Geynisman DM; Carles J; de Braud F; Joshua AM; Pérez-Gracia JL; Pérez CL; Shin SJ; Fang B; Barve M; Maruzzo M; Bracarda S; Kim M; Kerloeguen Y; Gallo JD; Maund SL; Harris A; Huang KC; Poon V; Sutaria DS; Gurney H, 2023, 'A Phase Ib, Open-label Study Evaluating the Safety and Efficacy of Ipatasertib plus Rucaparib in Patients with Metastatic Castration-resistant Prostate Cancer', Clinical Cancer Research, 29, pp. 3292 - 3300, http://dx.doi.org/10.1158/1078-0432.CCR-22-2585

Thavaneswaran S; Kansara M; Lin F; Espinoza D; Grady JP; Lee CK; Ballinger ML; Sebastian L; Corpuz T; Qiu MR; Mundra P; Bailey CG; Schmitz U; Simes J; Joshua AM; Thomas DM, 2023, 'A signal-seeking Phase 2 study of olaparib and durvalumab in advanced solid cancers with homologous recombination repair gene alterations', British Journal of Cancer, 129, pp. 475 - 485, http://dx.doi.org/10.1038/s41416-023-02311-0

Pham JP; On L; Ardolino L; Hurwitz J; Salaun H; Sim HW; Joshua AM, 2023, 'Efficacy of immune checkpoint inhibition in metastatic uveal melanoma: a systematic review and meta-analysis', Melanoma Research, 33, pp. 316 - 325, http://dx.doi.org/10.1097/CMR.0000000000000900

Pant S; Schuler M; Iyer G; Witt O; Doi T; Qin S; Tabernero J; Reardon DA; Massard C; Minchom A; Lugowska I; Carranza O; Arnold D; Gutierrez M; Winter H; Stuyckens K; Crow L; Najmi S; Hammond C; Thomas S; Santiago-Walker A; Triantos S; Sweiti H; Loriot Y; Greco MA; Coward J; Joshua A; Karapetis C; Hart C; Zhang A; Prenen H; Goeminne JC; Machiels JP; Rottey S; Corassa M; Molin GZD; Tiscoski K; Jardim DLF; Mak M; Fu W; Yao H; Huang J; Jiang H; Chen B; Yan D; Yang Y; Le Tourneau C; Penel N; Salas S; Blay JY; Brachet PE; Durando X; Emambux S; Ravaud A; Folprecht G; Ahrens M; Golf A; Haag GM; Lordick F; Desuki A; Cazzaniga M; Ciardiello F; Milella M; Koyama T; Hirooka Y; Okamoto W; Aogi K; Kuboki Y; Lee J; Kim SB; Ahn MJ; Chang JH; Kim YM; Nam DH; Park JS; Paz-Ares L; Moreno V; Cervantes A; Calvo M; Falcon A; Gonzalez A; Martinez Bueno A; García-Corbacho J; Longo F; Yen CJ; Chen JS; Hou MF; Chao Y; Rau KM; Chiu TJ; Feng YH; Hsu CH; Huang WT; Lai KM; Yeh SP; Palmer D; Welsh L; Plummer R; Iyer G; Bilen M, 2023, 'Erdafitinib in patients with advanced solid tumours with FGFR alterations (RAGNAR): an international, single-arm, phase 2 study', The Lancet Oncology, 24, pp. 925 - 935, http://dx.doi.org/10.1016/S1470-2045(23)00275-9

Choi WWY; Sánchez C; Li JJ; Dinarvand M; Adomat H; Ghaffari M; Khoja L; Vafaee F; Joshua AM; Chi KN; Guns EST; Hosseini-Beheshti E, 2023, 'Extracellular vesicles from biological fluids as potential markers in castration resistant prostate cancer', Journal of Cancer Research and Clinical Oncology, 149, pp. 4701 - 4717, http://dx.doi.org/10.1007/s00432-022-04391-6

Smith MR; Sandhu S; George DJ; Chi KN; Saad F; Thiery-Vuillemin A; Ståhl O; Olmos D; Danila DC; Gafanov R; Castro E; Moon H; Joshua AM; Mason GE; Espina BM; Liu Y; Lopez-Gitlitz A; Francis P; Bevans KB; Fizazi K, 2023, 'Health-related quality of life in GALAHAD: A multicenter, open-label, phase 2 study of niraparib for patients with metastatic castration-resistant prostate cancer and DNA-repair gene defects', Journal of Managed Care and Specialty Pharmacy, 29, pp. 758 - 768, http://dx.doi.org/10.18553/jmcp.2023.29.7.758

Chi KN; Rathkopf D; Smith MR; Efstathiou E; Attard G; Olmos D; Lee JY; Small EJ; Pereira De Santana Gomes AJ; Roubaud G; Saad M; Zurawski B; Sakalo V; Mason GE; Francis P; Wang G; Wu D; Diorio B; Lopez-Gitlitz A; Sandhu S; Alvarez M; Gatica G; Greco M; Korbenfeld E; Metrebian E; Salinas J; Salvatierra A; Tatangelo M; Ferguson T; Gurney H; Hovey E; Joshua A; Marco M; Marx G; Morris M; Ng S; Pook D; Tafreshi A; Tan TH; Tosheva T; Andrade L; Cruz F; Faria L; Figueiredo J; Franke F; Gomes AJ; Kann A; Kussumoto C; Martins S; Murad A; Pinczowski H; Pioner G; Pires L; Preto D; Santos G; Silva E; Silva J; Viana L; Vianna K; Paula A; Chen Z; Emmenegger U; Fleshner N; Parimi S; Saad F; Vera-Badillo F; Guo H; Luo H; Ma L; Qui M; Xue W; Yonglian G; Li L; Pu J; Zheng S; Zou Q; Brodak M; Hora M; Samal V; Student V; Vanasek J; Bompas E; Barthelemy P; Borchiellini D; Flechon A; Mahammedi H; Thiery-Vuillemin A; Tosi D; Dominique S; Helissey C; Boegemann M; Feyerabend S; Hellmis E; Schostak M; Lydon A; Sayers I; Parikh O, 2023, 'Niraparib and Abiraterone Acetate for Metastatic Castration-Resistant Prostate Cancer', Journal of Clinical Oncology, 41, pp. 3339 - 3351, http://dx.doi.org/10.1200/JCO.22.01649

Pham JP; Joshua AM; da Silva IP; Dummer R; Goldinger SM, 2023, 'Chemotherapy in Cutaneous Melanoma: Is There Still a Role?', Current Oncology Reports, 25, pp. 609 - 621, http://dx.doi.org/10.1007/s11912-023-01385-6

Horvath L; Lin H-M; Huynh K; Meikle T; Joshua AM; Azad A; Tan W; Butler L; Meikle P, 2023, 'Circulating ether lipids in prostate cancer.', Journal of Clinical Oncology, 41, pp. e17009 - e17009, http://dx.doi.org/10.1200/jco.2023.41.16_suppl.e17009

Hamid A; Gupta S; Keerthikumar S; Pasam A; Crumbaker M; Joshua AM; Lam E; Wenstrup R; Emmett L; Goode DL; Hofman MS; Sandhu S, 2023, 'Circulating tumor cells (CTCs) in patients with metastatic castration resistant prostate cancer (mCRPC) treated with olaparib plus 177lutetium-prostate specific membrane antigen-617 (177Lu-PSMA-617) in the LuPARP trial.', Journal of Clinical Oncology, 41, pp. 5064 - 5064, http://dx.doi.org/10.1200/jco.2023.41.16_suppl.5064

Sandhu S; Joshua AM; Emmett L; Crumbaker M; Bressel M; Huynh R; Banks PD; Wallace R; Hamid A; Inderjeeth AJ; Tran B; Azad A; Alipour R; Kong G; Ravi Kumar A; Saghebi J; Williams S; Akhurst TJ; Hicks RJ; Hofman MS, 2023, 'LuPARP: Phase 1 trial of 177Lu-PSMA-617 and olaparib in patients with metastatic castration resistant prostate cancer (mCRPC).', Journal of Clinical Oncology, 41, pp. 5005 - 5005, http://dx.doi.org/10.1200/jco.2023.41.16_suppl.5005

Lin FP-Y; Joshua AM; Epstein RJ, 2023, 'Machine learning prediction of patient-reported outcomes associated with systemic therapy from medical records.', Journal of Clinical Oncology, 41, pp. e13564 - e13564, http://dx.doi.org/10.1200/jco.2023.41.16_suppl.e13564

O'day R; Conway M; Lim L-A; McKenzie J; Atkinson V; Glasson W; McGrath L; Cherepanoff S; Gray E; Maurer MA; O'Quigley M; Shackleton MJ; Joshua AM, 2023, 'NADOM trial: Neoadjuvant/adjuvant trial of darovasertib in ocular melanoma (OM).', Journal of Clinical Oncology, 41, pp. TPS9612 - TPS9612, http://dx.doi.org/10.1200/jco.2023.41.16_suppl.tps9612

Thavaneswaran S; Mersiades A; Lin FP-Y; Espinoza D; Grady JP; Lee CK; Desai J; Brown MP; Grimison PS; O'Byrne KJ; Harrup RA; Nagrial A; Sebastian L; Chinchen S; Kansara M; Craft PS; Millward M; Simes J; Joshua AM; Thomas DM, 2023, 'Trastuzumab emtansine (T-DM1) in advanced cancers with HER2 mutations or amplification: Results from the Molecular Screening and Therapeutics (MoST) Program substudy.', Journal of Clinical Oncology, 41, pp. 3127 - 3127, http://dx.doi.org/10.1200/jco.2023.41.16_suppl.3127

Rodrigues A; Cosman R; Joshua AM, 2023, 'Correction To: LXS196 for Metastatic Uveal Melanoma - finally some progress (British Journal of Cancer, (2023), 128, 10, (1791-1793), 10.1038/s41416-023-02199-w)', British Journal of Cancer, 128, pp. 1976, http://dx.doi.org/10.1038/s41416-023-02231-z

Rodrigues A; Cosman R; Joshua AM, 2023, 'LXS196 for Metastatic Uveal Melanoma - finally some progress', British Journal of Cancer, 128, pp. 1791 - 1793, http://dx.doi.org/10.1038/s41416-023-02199-w

Conway JRW; Warren SC; Lee YK; McCulloch AT; Magenau A; Lee V; Metcalf XL; Stoehr J; Haigh K; Abdulkhalek L; Guaman CS; Reed DA; Murphy KJ; Pereira BA; Mélénec P; Chambers C; Latham SL; Lenthall H; Deenick EK; Ma Y; Phan T; Lim E; Joshua AM; Walters S; Grey ST; Shi YC; Zhang L; Herzog H; Croucher DR; Philp A; Scheele CLGJ; Herrmann D; Sansom OJ; Morton JP; Papa A; Haigh JJ; Nobis M; Timpson P, 2023, 'Monitoring AKT activity and targeting in live tissue and disease contexts using a real-time Akt-FRET biosensor mouse', Science Advances, 9, http://dx.doi.org/10.1126/sciadv.adf9063

Jamal S; Nagrial A; Carlino M; Cosman R; Joshua A; Eek R; Piha-Paul S; Hamid O; Liu J, 2023, 'Abstract CT267: ENB-003, an ETBR antagonist, in combination with pembrolizumab for advanced solid tumor: The ENBolden trial', Cancer Research, 83, pp. CT267 - CT267, http://dx.doi.org/10.1158/1538-7445.am2023-ct267

Sweeney CJ; Martin AJ; Stockler MR; Begbie S; Cheung L; Chi KN; Chowdhury S; Frydenberg M; Horvath LG; Joshua AM; Lawrence NJ; Marx G; McCaffrey J; McDermott R; McJannett M; North SA; Parnis F; Parulekar W; Pook DW; Reaume MN; Sandhu SK; Tan A; Tan TH; Thomson A; Vera-Badillo F; Williams SG; Winter D; Yip S; Zhang AY; Zielinski RR; Davis ID; Abdi E; Allan S; Bastick P; Blum R; Briscoe K; Brungs D; Bydder S; Chittajallu BR; Cronk M; Cuff K; Dowling A; George M; Horvath L; Hovey E; Joshua A; Karanth N; Kichenadasse G; Krieger L; Mathlum M; Nott L; Otty Z; Pook D; Sandhu S; Sewak S; Stevanovic A; Stockler M; Suder A; Tan H; Torres J; Troon S; Underhill C; Weickhardt A; Zielinski R; Abbas T; Anan G; Booth C; Campbell H; Chin J; Chouinard E; Donnelly B; Drachenberg D; Faghih A; Finelli A; Hotte S; Noonan K; North S; Rassouli M; Reaume N; Rendon R; Saad F; Sadikov E; Vigneault E; Zalewski P; Morris P; O'Connor M; Donnellan P; O'Donnell D; Edwards J; Fong P; Crabb S; Khan O; Khoo V; Macdonald G; Payne H; Robinson A; Shamash J; Staffurth J; Thomas C, 2023, 'Testosterone suppression plus enzalutamide versus testosterone suppression plus standard antiandrogen therapy for metastatic hormone-sensitive prostate cancer (ENZAMET): an international, open-label, randomised, phase 3 trial', The Lancet Oncology, 24, pp. 323 - 334, http://dx.doi.org/10.1016/S1470-2045(23)00063-3

Sandhu S; Subramaniam S; Hofman MS; Stockler MR; Martin AJ; Pokorski I; Goh JC; Pattison DA; Dhiantravan N; Gedye C; Rutherford NK; Joshua AM; Tan TH; Kirkwood ID; Lee ST; Weickhardt AJ; Alipour R; Nguyen A; Davis ID; Emmett L, 2023, 'Evolution: Phase II study of radionuclide 177Lu-PSMA-617 therapy versus 177Lu-PSMA-617 in combination with ipilimumab and nivolumab for men with metastatic castration-resistant prostate cancer (mCRPC; ANZUP 2001).', Journal of Clinical Oncology, 41, pp. TPS271 - TPS271, http://dx.doi.org/10.1200/jco.2023.41.6_suppl.tps271

Gupta S; Hamid A; Fernandez L; Pasam A; Lam E; Tubbs A; Bourdon D; Emmett L; Joshua AM; Hofman MS; Wenstrup R; Sandhu S, 2023, 'Performance of a blood-based liquid biopsy test to detect PSMA expression on circulating tumor cells in men with metastatic prostate cancer.', Journal of Clinical Oncology, 41, pp. 256 - 256, http://dx.doi.org/10.1200/jco.2023.41.6_suppl.256

Azad A; Voskoboynik M; Palma dos Reis AF; Joshua AM; Weickhardt AJ; Jones RJ; Rescigno P; Tran B; Kennedy C; Linardopoulos S; Moorthy G; Zhou TJ; Brown JS; Lukacs E; Francis R; Hudson A, 2023, 'Phase 1/2a study of AZD5305, a novel poly(adenosine diphosphate ribose) polymerase (PARP) 1-selective inhibitor in combination with new hormonal agents (NHAs) in patients (pts) with metastatic prostate cancer (mPC).', Journal of Clinical Oncology, 41, pp. TPS296 - TPS296, http://dx.doi.org/10.1200/jco.2023.41.6_suppl.tps296

Carvajal RD; Sacco JJ; Jager MJ; Eschelman DJ; Olofsson Bagge R; Harbour JW; Chieng ND; Patel SP; Joshua AM; Piperno-Neumann S, 2023, 'Advances in the clinical management of uveal melanoma', Nature Reviews Clinical Oncology, 20, pp. 99 - 115, http://dx.doi.org/10.1038/s41571-022-00714-1

Pathmanandavel S; Crumbaker M; Ho B; Yam AO; Wilson P; Niman R; Ayers M; Sharma S; Hickey A; Eu P; Stockler M; Martin AJ; Joshua AM; Nguyen A; Emmett L, 2023, 'Evaluation of 177Lu-PSMA SPECT Quantitation as a Response Biomarker within a Prospective 177Lu-PSMA-617 and NOX66 Combination Trial (LuPIN)', Journal of Nuclear Medicine, 64, pp. 221 - 226, http://dx.doi.org/10.2967/jnumed.122.264398

John N; Pathmanandavel S; Crumbaker M; Counter W; Ho B; Yam AO; Wilson P; Niman R; Ayers M; Poole A; Hickey A; Agrawal S; Perkins G; Kallinen A; Eslick E; Stockler MR; Joshua AM; Nguyen A; Emmett L, 2023, '177Lu-PSMA SPECT Quantitation at 6 Weeks (Dose 2) Predicts Short Progression-Free Survival for Patients Undergoing 177Lu-PSMA-I&T Therapy', Journal of Nuclear Medicine, 64, pp. 410 - 415, http://dx.doi.org/10.2967/jnumed.122.264677

Hiong A; O'Day R; Fog LS; McKay D; McKenzie J; Ameratunga M; Joshua AM; Shackleton M, 2023, 'Globe Salvage and Vision Preservation by Neoadjuvant Darovasertib and Crizotinib in Uveal Melanoma', Ophthalmology Retina, http://dx.doi.org/10.1016/j.oret.2023.10.009

Emmett L; John N; Pathmanandavel S; Counter W; Ayers M; Sharma S; Agrawal S; Poole A; Hovey E; Pranavan G; Gedye C; Mallesara G; Guminski A; Lee A; Stockler MR; Hickey A; Eu P; Joshua AM; Crumbaker M; Nguyen A, 2023, 'Patient outcomes following a response biomarker-guided approach to treatment using 177Lu-PSMA-I&T in men with metastatic castrate-resistant prostate cancer (Re-SPECT)', Therapeutic Advances in Medical Oncology, 15, http://dx.doi.org/10.1177/17588359231156392

Pathmanandavel S; Crumbaker M; Nguyen A; Yam AO; Wilson P; Niman R; Ayers M; Sharma S; Eu P; Martin AJ; Stockler MR; Joshua AM; Emmett L, 2023, 'The Prognostic Value of Posttreatment 68Ga-PSMA-11 PET/CT and 18F-FDG PET/CT in Metastatic Castration-Resistant Prostate Cancer Treated with 177Lu-PSMA-617 and NOX66 in a Phase I/II Trial (LuPIN)', Journal of Nuclear Medicine, 64, pp. 69 - 74, http://dx.doi.org/10.2967/jnumed.122.264104

Pham JP; Hurwitz J; Cosman R; Goldinger SM; Sim H-W; Dummer R; Joshua AM, 2023, '1127P Efficacy of immune checkpoint inhibitors (ICIs) in advanced mucosal melanoma (MM): A systematic review and meta-analysis', Annals of Oncology, 34, pp. S677 - S677, http://dx.doi.org/10.1016/j.annonc.2023.09.2261

Goode D; Keerthikumar S; Gupta S; Joshua AM; Emmett L; Crumbaker M; Singer T; Lam E; Fernandez L; Jimenez E; Zhang D; Lin Y; Wenstrup RJ; PASAM A; Hicks R; Kong G; Hamid A; Sandhu SK, 2023, '1825P Molecular features of circulating tumour cells (CTCs) associate with response to 177Lu-PSMA-617 plus pembrolizumab for metastatic castration resistant prostate cancer (mCRPC)', Annals of Oncology, 34, pp. S988 - S989, http://dx.doi.org/10.1016/j.annonc.2023.09.2773

Horvath LG; Kench C; Mellor R; Lin H-M; Mak B; Scheinberg T; Mahon K; Graham L; Azad AA; Joshua AM; Stockler MR; Marx GM; Briscoe K; Samaras K, 2023, '1831P Dissecting the meaning of obesity in metastatic castration resistant prostate cancer: Size or metabolism?', Annals of Oncology, 34, pp. S991 - S991, http://dx.doi.org/10.1016/j.annonc.2023.09.2779

Gedye C; Harris CA; Stockler MR; Morris M; Ferguson T; Goh JCH; Martin A; Underhill CR; Pook D; Krieger LEM; Kichenadasse G; Joshi AJ; Subramaniam S; Zebic DS; Zhang A; Joshua AM; Toner GC; Vasey PA; Prithviraj P; Davis ID, 2023, '1886P Pembrolizumab and denosumab in clear cell renal cell carcinoma (ccRCC): A phase II trial (KeyPAD, ANZUP1601)', Annals of Oncology, 34, pp. S1014 - S1014, http://dx.doi.org/10.1016/j.annonc.2023.09.1116

Wong D; Luo P; Znassi N; Arteaga DP; Gray D; Danesh A; Han M; Zhao EY; Pedersen S; Prokopec S; Sundaravadanam Y; Torti D; Marsh K; Keshavarzi S; Xu W; Krema H; Joshua AM; Butler MO; Pugh TJ, 2023, 'Integrated, Longitudinal Analysis of Cell-free DNA in Uveal Melanoma.', Cancer Res Commun, 3, pp. 267 - 280, http://dx.doi.org/10.1158/2767-9764.CRC-22-0456


Back to profile page